Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
Status:
Completed
Trial end date:
2019-06-28
Target enrollment:
Participant gender:
Summary
Study to evaluate the safety, tolerability, antitumor activity, and pharmacology of MEDI-573
in combination with an aromatase inhibitor (AI) in adult subjects with HR+, HER2-negative
MBC.